Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 92.28 USD -0.38% Market Closed
Market Cap: 114.9B USD
Have any thoughts about
Gilead Sciences Inc?
Write Note

Gilead Sciences Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gilead Sciences Inc
Operating Income Peer Comparison

Comparables:
ABBV
AMGN
ALNY
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.9B
CAGR 3-Years
-3%
CAGR 5-Years
20%
CAGR 10-Years
-1%
Abbvie Inc
NYSE:ABBV
Operating Income
$15.4B
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
10%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Operating Income
-$188.1m
CAGR 3-Years
36%
CAGR 5-Years
26%
CAGR 10-Years
7%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.3B
CAGR 3-Years
17%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-18%
CAGR 5-Years
13%
CAGR 10-Years
18%

See Also

What is Gilead Sciences Inc's Operating Income?
Operating Income
10.9B USD

Based on the financial report for Sep 30, 2024, Gilead Sciences Inc's Operating Income amounts to 10.9B USD.

What is Gilead Sciences Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-1%

Over the last year, the Operating Income growth was 7%. The average annual Operating Income growth rates for Gilead Sciences Inc have been -3% over the past three years , 20% over the past five years , and -1% over the past ten years .

Back to Top